

Most Read This Week
- Prostate-Only vs Whole-Pelvic Radiation Therapy in High-Risk and Very High–Risk Prostate Cancer
- ASCO GU 2021: No Benefit From Radiation Dose Intensification in Salvage Radiotherapy for Recurrent Prostate Cancer
- ASCO GU 2021: Talazoparib Demonstrates Durable Antitumor Activity in Metastatic Castration-Resistant Prostate Cancer
- ASCO GU 2021: Final Results of ACIS Support Addition of Apalutamide to Abiraterone-Prednisone for Advanced Prostate Cancer
- ASCO GU 2021: Adjuvant Nivolumab for Advanced Urothelial Carcinoma Shows Benefits
Recently Updated
- Lenvatinib Plus Pembrolizumab Tops Sunitinib in Advanced RCC
- ASCO GU 2021: KEYNOTE-057 3-Year Follow-Up Continues to Demonstrate Benefits of Pembrolizumab in High-Risk Non-Muscle Invasive Bladder Cancer
- ASCO GU 2021: Lenvatinib-Pembrolizumab Emerges as Best Option for First-Line Treatment of Renal Cell Carcinoma in CLEAR Trial
- Decipher Genomic Classifier in Prostate Cancer
- Enfortumab Vedotin Prolongs Survival in Advanced Urothelial Cancer